
Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Implantica
31,9
SEK
0 %
Alle 1K seuraajaa
IMP A SDB
First North Stockholm
Medical Equipment & Services
Health Care
Yleiskuva
Luvut & ennusteet
Omistajat
0%
−20,25%
−7,27%
−13,32%
−25,73%
+9,25%
−33,33%
-
−66,96%
Implantica is active in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes implantable medical instruments, which are further used for the treatment of diseases that affect the esophagus. In addition to the main business, service and related ancillary services are also offered, especially focused on eHealth. Implantica operates worldwide, with the largest presence in North America and Europe.
Lue lisääMarkkina-arvo
37,74 mrd. SEK
Vaihto
356,06 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
9.5.
2025
Osavuosikatsaus Q1'25
15.5.
2025
Yhtiökokous '25
14.8.
2025
Osavuosikatsaus Q2'25
Kaikki
Webcastit
Tiedotteet
NäytäKaikki sisältötyypit

Implantica publishes Year-end Report, January - December 2024 (Q4)
Implantica announces positive feedback received from U.S. FDA of the RefluxStop™ PMA Module 2 submission
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Implantica announces Module 1 is accepted and closed by FDA in the PMA application for RefluxStop™
Implantica presents the Year-end Report (Q4 2024) on February 14 at 15:00 CET
Implantica announces onboarding of the world-leading La Paz University Hospital, Spain
Implantica announces completion of first GI-focused RefluxStop™ educational meeting by a prestigious NHS Hospital in the UK
Implantica announces new exceptional published data from the largest real-world study from Germany
Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration
Implantica to be included in Nasdaq's First North 25 index
Implantica strengthens the strategic RefluxStop™ expansion with the addition of yet another key University Hospital in Germany with several more in the pipeline
Implantica announces two new RefluxStop™ University Hospitals in Spain, leading to 10 active centers and many more to join soon
Implantica deepens market penetration in Italy with the addition of the ninth RefluxStop™ Center of Excellence and several lined up to start near-term
